


**Supplemental Information**


**$\Delta$ Np63 Inhibits Oxidative Stress-Induced Cell  
Death, Including Ferroptosis, and Cooperates with  
the BCL-2 Family to Promote Clonogenic Survival**

**Gary X. Wang, Ho-Chou Tu, Yiyu Dong, Anders Jacobsen Skanderup, Yufeng Wang, Shugaku Takeda, Yogesh Tengarai Ganesan, Song Han, Han Liu, James J. Hsieh, and Emily H. Cheng**


## Supplemental Information



**Supplemental Figure S1. Characterization of DNA damage-induced programmed necrotic death in *Bax*<sup>-/-</sup>*Bak*<sup>-/-</sup> DKO MEFs.** (A) SV40-transformed *Bax*<sup>-/-</sup>*Bak*<sup>-/-</sup> DKO MEFs were transfected with scrambled siRNA (siScr) or siRNA against *RIP1*. Cell lysates were analyzed by immunoblots using the indicated antibodies. (B) Cells described in (A) were treated with etoposide (10 µg/ml) for 3 days. (C) SV40-transformed *Bax*<sup>-/-</sup>*Bak*<sup>-/-</sup> DKO MEFs were treated with the indicated agents for 3 days. (D) SV40-transformed *Bax*<sup>-/-</sup>*Bak*<sup>-/-</sup> DKO cells were treated with etoposide, etoposide plus N-acetyl-L-cysteine (NAC, 25 mM), or etoposide plus ferrostatin-1 (10 µM) for 3 days. (E) SV40-transformed *Bax*<sup>-/-</sup>*Bak*<sup>-/-</sup> DKO cells were treated with etoposide, etoposide plus deferoxamine (DFO, 80 µM), or etoposide plus Tiron (10 mM) for 3 days. Cell death in (B-E) was quantified by flow cytometric analysis following propidium iodide staining (mean ± s.d., n = 3 independent experiments). \* *P* < 0.05.




**Supplemental Figure S2. Characterization of DNA damage-induced programmed necrotic death in *p53*<sup>-/-</sup>*Bax*<sup>-/-</sup>*Bak*<sup>-/-</sup> TKO MEFs.** (A) Primary MEFs isolated from two *Bax*<sup>-/-</sup>*Bak*<sup>-/-</sup> embryos and two *p53*<sup>-/-</sup>*Bax*<sup>-/-</sup>*Bak*<sup>-/-</sup> embryos were transformed by E1A and Ras. E1A/Ras-transformed *Bax*<sup>-/-</sup>*Bak*<sup>-/-</sup> and *p53*<sup>-/-</sup>*Bax*<sup>-/-</sup>*Bak*<sup>-/-</sup> MEFs were treated with etoposide (10 μg/ml). Cell death was quantified by annexin-V staining at the indicated times (mean ± s.d., n = 3). (B) SV40-transformed *Bax*<sup>-/-</sup>*Bak*<sup>-/-</sup> or *p53*<sup>-/-</sup>*Bax*<sup>-/-</sup>*Bak*<sup>-/-</sup> MEFs were untreated or treated with etoposide. Cell death was quantified by propidium iodide staining at the indicated times (mean ± s.d., n = 3). (C) SV40-transformed *p53*<sup>-/-</sup>*Bax*<sup>-/-</sup>*Bak*<sup>-/-</sup> MEFs were treated with etoposide or etoposide plus N-acetyl-L-cysteine (NAC, 20 mM) or etoposide plus diphenyleneiodonium (DPI, 100 nM) for the indicated times. Cell death was quantified by propidium iodide staining at the indicated times (mean ± s.d., n = 3). (D) ΔNp63α prevents DNA damage-induced ROS accumulation in *p53*<sup>-/-</sup>*Bax*<sup>-/-</sup>*Bak*<sup>-/-</sup> MEFs. SV40-transformed *p53*<sup>-/-</sup>*Bax*<sup>-/-</sup>*Bak*<sup>-/-</sup> MEFs transduced with control or ΔNp63α-expressing retrovirus were mock treated or treated with etoposide. Oxidation of the ROS-sensitive dye CM-H<sub>2</sub>DCFDA or MitoSOX Red was quantified by flow cytometric analysis. Data shown are fold increase of ROS after etoposide treatment (mean ± s.d., n = 3). \* *P* < 0.05.




**Supplemental Figure S3. Characterization of p63 isoform expression and validation of knockdown in MEFs.** (A) A schematic of modular structure of the p63 isoforms. (B) cDNA prepared from *Bax<sup>-/-</sup>Bak<sup>-/-</sup>* DKO MEFs transduced with GFP or  $\Delta$ Np63 $\alpha$ -expressing retrovirus was subjected to PCR using primers specific for all isoforms of p63 (Pan), TA isoforms of p63 (TA), or  $\Delta$ N isoforms of p63 ( $\Delta$ N). (C) SV40-transformed *Bax<sup>-/-</sup>Bak<sup>-/-</sup>* DKO MEFs transduced with retrovirus expressing shRNA against luciferase or p63, or transfected with scrambled siRNA (siScr) or siRNA against p63 were subjected to quantitative RT-PCR analysis for p63 expression. Data presented as mean  $\pm$  SD from three independent experiments. (D) SV40-transformed *Bax<sup>-/-</sup>Bak<sup>-/-</sup>* DKO MEFs, transfected with scrambled siRNA (siScr) or siRNA against p63 for 3 days, were mock treated or treated with etoposide (10  $\mu$ g/ml) for 3 days. DKO

MEFs transduced with retrovirus expressing shRNA against luciferase or p63 were mock treated or treated with etoposide for 3 days. Cell death was quantified by propidium iodide staining (mean  $\pm$  s.d.,  $n = 3$ ). (E) SV40-transformed *p53<sup>-/-</sup>Bax<sup>-/-</sup>Bak<sup>-/-</sup>* TKO MEFs, transfected with scrambled siRNA (siScr) or siRNA against p63 for 3 days, were mock treated or treated with etoposide for 5 days. TKO MEFs transduced with retrovirus expressing shRNA against luciferase or p63 were mock treated or treated with etoposide for 5 days. Cell death was quantified by propidium iodide staining (mean  $\pm$  s.d.,  $n = 3$ ). (F) *Bax<sup>-/-</sup>Bak<sup>-/-</sup>* DKO MEFs transfected with scrambled siRNA (siScr) or siRNA against *Idh2* were analyzed by immunoblots using the indicated antibodies. (G) *Bax<sup>-/-</sup>Bak<sup>-/-</sup>* DKO MEFs transfected with scrambled siRNA (siScr) or siRNA against *Gclc*, *Gss*, or *Gpx2* were analyzed by qRT-PCR using the indicated gene-specific primers. Data presented as mean  $\pm$  SD from three independent experiments. \*  $P < 0.05$ .



**Supplemental Figure S4.  $\Delta Np63\alpha$  upregulates glutathione metabolic pathway genes and the protective effect of  $\Delta Np63\alpha$  against oxidative stress-induced cell death is mitigated by the GCLC inhibitor buthionine sulfoximine (BSO).** (A) A heatmap representation of glutathione metabolism genes differentially regulated by  $\Delta Np63\alpha$ . *Bax*<sup>-/-</sup>*Bak*<sup>-/-</sup> DKO cells transduced with retrovirus expressing GFP or  $\Delta Np63\alpha$  were mock treated or treated with etoposide (10  $\mu$ g/ml) for 6 hours. The gene expression profiles were assessed using the Affymetrix GeneChip Mouse Gene 1.0 ST array and analyzed for genes involved in glutathione metabolism. (B) SV40-transformed *Bax*<sup>-/-</sup>*Bak*<sup>-/-</sup> DKO MEFs stably expressing GFP or  $\Delta Np63\alpha$  were treated with the indicated agents for 3 days. Cell death was quantified by propidium iodide staining (mean  $\pm$  s.d., n = 3 independent experiments). \*  $P < 0.05$ .




**Supplemental Figure S5. Knockdown of ΔNp63α but not TAp63 induces ROS accumulation and sensitizes cells to chemotherapeutic agent-induced cell death.**


(A) ME-180 cells were transduced with lentivirus expressing doxycycline-inducible miR30-based shRNA against all p63 isoforms. Cells were untreated or treated with doxycycline (2 μg/ml) for three days and analyzed for ROS production and immunoblots using the indicated antibodies. Oxidation of the ROS-sensitive dye H<sub>2</sub>DCFDA was quantified by flow cytometric analysis. Data shown are fold increase of ROS induced by knockdown of p63 (mean ± s.d., n = 3). (B) ME-180 cells transfected with scrambled

siRNA (siScr) or siRNA against  $\Delta Np63$  for 3 days were subjected to analysis for ROS production or immunoblot analysis using the indicated antibodies. Oxidation of the ROS-sensitive dye H<sub>2</sub>DCFDA was quantified by flow cytometric analysis. Data shown are fold increase of ROS induced by knockdown of  $\Delta Np63$  (mean  $\pm$  s.d., n = 3). (C) MCF-10A cells, transfected with scrambled siRNA or siRNA against *TAp63* or  $\Delta Np63$ , were subjected to qRT-PCR analysis for the indicated p63 isoform as well as immunoblot analysis using the indicated antibodies. qRT-PCR data were normalized against GAPDH (mean  $\pm$  s.d., n = 3). (D) MCF-10A cells, transfected with scrambled siRNA or siRNA against *TAp63* or  $\Delta Np63$ , were subjected to CM-H<sub>2</sub>DCFDA staining followed by flow cytometric analysis. Data shown are fold increase of ROS induced by knockdown of *TAp63* or  $\Delta Np63$  (mean  $\pm$  s.d., n = 3). (E) MCF-10A cells transduced with lentivirus expressing shRNA against GFP or p63 for 48 hours were untreated or treated with doxorubicin (1  $\mu$ g/ml) for 27 hours. Cell death was quantified by propidium iodide (PI) staining (mean  $\pm$  s.d., n = 3). (F) ME-180 cells transduced with lentivirus expressing shRNA against GFP or p63 for 48 hours were mock treated or treated with cisplatin (10  $\mu$ M) for 32 hours. Cell death was quantified by propidium iodide (PI) staining (mean  $\pm$  s.d., n = 3). (G) ME-180 cells, transfected with scrambled siRNA or siRNA against *TAp63*, were subjected to qRT-PCR analysis of *TAp63*,  $\Delta Np63$ , and *SLC7A11* mRNA. Data were normalized against GAPDH (mean  $\pm$  s.d., n = 3). (H) ME-180 cells, transfected with scrambled siRNA or siRNA against *TAp63*, were mock treated or treated with erastin (20  $\mu$ M) for 72 h. Cell death was quantified by propidium iodide staining (mean  $\pm$  s.d., n = 3). \*,  $P < 0.05$ .






**Supplemental Figure S6. Ferrostatin-1 has minimal effect on the luminal clearance of mammary acini in three-dimensional culture.** MCF-10A cells transduced with retrovirus expressing GFP or BCL-2 were cultured in reconstituted basement membrane (Matrigel)  $\pm$  ferrostatin-1 for 28 days. Acini were fixed and stained for Laminin 5 (red) and nuclear stain DAPI (blue). Representative confocal microscopy images from two independent experiments are shown. Scale bar, 25  $\mu$ m.



**Intrinsic Death Signals Induce both BAX/BAK-Dependent Apoptosis and BAX/BAK-Independent Oxidative Stress**



**Combined Inhibition of Apoptosis and Oxidative Stress Promotes Clonogenic Survival upon Intrinsic Death Signals**

**Supplemental Figure S7.** Model depicts the apoptotic and non-apoptotic cell death pathways activated by DNA damage and loss of matrix attachment, respectively.

Gene	Cat#	Sequences
mouse <i>Idh2</i> #1	Ambion s114463	5'-AGACUGACUUCGACAGGAAtt
mouse <i>Idh2</i> #2	Ambion 95489	5'-GGAAUAAGAUCUGGUAUGAtt
mouse <i>Gclc</i> #1	Ambion s66718	5'-CGGUAUGACUCAAUAGAUAtt
mouse <i>Gclc</i> #2	Ambion s201400	5'-GGGUGAUCCUCUCAUACAAtt
mouse <i>Gss</i> #1	Ambion s67110	5'-GCCCAGUCAGUAUAAUUCAtt
mouse <i>Gss</i> #2	Ambion s67112	5'-CCAUCAAAAAGGACGACUAtt
mouse <i>Gpx2</i> #1	Dharmacon siGenome-02	5'-UCAAUGAGCUGCAAUGUCG
mouse <i>Gpx2</i> #2	Dharmacon siGenome-03	5'-CAACUACCCGGGACUACAA
mouse <i>Nrf2</i>	Ambion s70523	5'-CAUUUUUACUCAUCGAUCUtt
mouse <i>p63</i>	Dharmacon siGenome-04	5'-CCACCGAACUGAAGAAGCU
human $\Delta Np63$	Dharmacon siGenome-08	5'-CGACAGUCUUGUACAAUUU
human <i>TAp63</i>	Dharmacon siGenome-06	5'-CAAACAAGAUUGAGAUUAG
mouse <i>Rip1</i> #1	Ambion s72975	5'-GGUGGUACCCUUUACUACAtt
mouse <i>Rip1</i> #2	Ambion s72977	5'-GGAUUUGGAACUACAGGUAtt

**Table S1.** Summary of siRNA oligos.

<b>Gene</b>	<b>Sequences of Primers for qRT-PCR</b>
mouse p63 pan-isoform	5'-CCTTTCCGTCAGAATACACACGGA-3'
mouse p63 pan-isoform	5'-GTTTCTGAAGTAGGTGCTGGTGCT-3'
mouse <i>TAp63</i> isoform	5'-CCTATATGCTCAGTACAGCCCATCG-3'
mouse <i>TAp63</i> isoform	5'-CTATTCTGTGCGTGGTCTGTGTTGT-3'
mouse $\Delta Np63$ isoform	5'-TCTTAGAAGATTTCGCAGCGCAAGG-3'
mouse $\Delta Np63$ isoform	5'-CTATTCTGTGCGTGGTCTGTGTTGT-3'
mouse <i>Gclc</i>	5'-TACACCTGGATGATGCCAACGA-3'
mouse <i>Gclc</i>	5'-GTCAACCTTGGACAGCGGAATG-3'
mouse <i>Gss</i>	5'-CCTGATGCTAGAGAGATCTCGTGC-3'
mouse <i>Gss</i>	5'-CTCTCTCCTCACTGTCCTTCAGC-3'
mouse <i>Idh2</i>	5'-CCTGATGACATCTGTGCTGGTCT-3'
mouse <i>Idh2</i>	5'-GAGCTCTGTCCAGGTTGCTCTT-3'
mouse <i>Nrf2 (Nfe2l2)</i>	5'-ATCCAGACAGACACCAGTGGATC-3'
mouse <i>Nrf2 (Nfe2l2)</i>	5'-CAAACCTTGCTCCATGTCCTGCTC-3'
mouse <i>Slc7a11</i>	5'-GTGGTGTGTTTCGCTGTCTCCA-3'
mouse <i>Slc7a11</i>	5'-CGGAGAAGAGCATCACCATCGTC-3'
human p63 pan-isoform	5'-AGAACGGTGATGGTACGAAGCG-3'
human p63 pan-isoform	5'-GTA CTGCATGAGTTCCAGGGACTC-3'
human <i>TAp63</i> isoform	5'-AAGATGGTGCGACAAACAAG-3'
human <i>TAp63</i> isoform	5'-AGAGAGCATCGAAGGTGGAG-3'
human $\Delta Np63$ isoform	5'-GGAAAACAATGCCCAGACTC-3'
human $\Delta Np63$ isoform	5'-GTGGAATACGTCCAGGTGGC-3'
human <i>GSS</i>	5'-GACCAGCGTGCCATAGAGAATGA-3'
human <i>GSS</i>	5'-CATGTGACCTCTCCAGCAGTAGAC-3'
human <i>IDH2</i>	5'-GATGGGAAGACGATTGAGGCTGA-3'
human <i>IDH2</i>	5'-TCAGGAAGTGCTCGTTCAGCTT-3'
human <i>GSR</i>	5'-CCAACGTCAAAGGCATCTATGCAG-3'
human <i>GSR</i>	5'-ATCTTCCGTGAGTCCCACTGTC-3'
human <i>SLC7A11</i>	5'-GTTGCGTCTCGAGAGGGTCA-3'
human <i>SLC7A11</i>	5'-GTCGAGGTCTCCAGAGAAGAGC-3'

**Table S2.** Summary of Primers for qRT-PCR.